Skip Navigation

ACS is committed to helping combat the global COVID-19 pandemic with initiatives and free resources. Learn More

Richard Olson

Richard Olson

Rick obtained his Ph.D. with Hans Reich at the University of Wisconsin, then joined DuPont, where he worked on antifungal, cardiovascular and central nervous system therapies.  He joined Bristol-Myers Squibb in 2001, where he has led teams identifying clinical candidates for depression, schizophrenia and Alzheimer's Disease. He is currently a Research Fellow in the Discovery Chemistry Platforms Department, and is the chemistry lead for BMS efforts directed towards antisense oligonucleotides.